The case for & against
Bull & Bear analysis
Abbott Laboratories (NYSE: ABT) is a leading global healthcare company engaged in the development and marketing of a diverse range of healthcare products spanning medical devices, diagnostics, nutrition, and pharmaceuticals. Its strategic positioning and broad portfolio allow it to capture growth across multiple markets, particularly in high-demand areas such as diabetes care and cancer diagnostics. With recent expansion moves, notably the acquisition of Exact Sciences, Abbott is fortifying its presence in oncology, aligning its growth strategy with essential healthcare trends.
Bull says
- ↑Q1 revenue $11.16B (+3.7%), adjusted EPS $1.15 (+6% YoY)
- ↑Exact Sciences acquisition to contribute ~$3B sales in 2026
- ↑Medical devices revenue +12% to $2B, driven by FreeStyle Libre
- ↑CGM sales $1.9B (+19.5%) reflects rising diabetes demand
- ↑Dividend yield 2.7% offers a reliable income stream
- ↑Strong qualitative factors: high dividend yield, solid financial quality, low volatility
Bear says
- ↓Diagnostics segment sales declined 1.5% due to reduced COVID testing
- ↓China’s volume‐based procurement cuts volumes and prices
- ↓Tariffs could cost a few hundred million in 2025, hitting margins
- ↓Negative analyst revisions signal weakening earnings outlook
- ↓Negative earnings yield and momentum factors suggest growth risks
- ↓Geopolitical tensions in China may disrupt supply chains
Investment themes with ABT
Companies paying above-average dividends
Companies with strong fundamentals and stability
Devices and instruments for medical treatment
Earnings Call · Q2 2025 · Mgmt. Guidance